

# ASX Announcement 28 June 2022

#### STRATEGIC DISTRIBUTION PARTNERSHIP – ADDITIONAL INFORMATION

Optiscan Imaging Limited (ASX: OIL) ('the Company' or 'Optiscan') provides the following additional information at the request of ASX in relation to its ASX Announcement dated 27 June 2022 and titled 'Optiscan announces Strategic Distribution Partner for China' whereby the Company announced a new Distribution Agreement (Agreement) with China based Sinsi Technology Co Ltd (Distributor).

The Company advises that the Agreement has an initial term of 2 years (Initial Term) with the ability to extend for another 12 months (Additional Term) following the Initial Term. The Agreement includes minimum purchase targets for the Distributor and if these targets are achieved the revenue will be material for the Company in the future.

The Agreement may be terminated by the Company in the event that the Distributor has not made payment in accordance with the Agreement and any notices of default being provided. Either party may terminate the Agreement in the event of any breach of the Agreement.

This announcement has been authorised for release by the Board of Optiscan.

--ends-

#### For investor queries, please contact:

Prof Camile Farah
CEO & Managing Director – Optiscan Imaging Ltd
E: cfarah@optiscan.com

For more information about our products, visit www.optiscan.com

### **About Optiscan**

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* imaging at the sub-cellular level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pensized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

## **About Sinsi Technology Co Ltd**

Sinsi Technology has over 20 years of experience representing a range of international organisations in China in the life science and biotechnology sectors. They focus on domestic integration and advancement of global products into the China research and development market space. They also have an established service network across greater China which further enhances their ability to represent Optiscan to the market.

#### Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of OptiScan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate", "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of OptiScan that could cause actual results to differ from the results expressed or anticipated in these statements.